Bridge Therapeutics, Inc. logo

Bridge Therapeutics, Inc.

Bridge Therapeutics, Inc. is a development-stage pharmaceutical company pursuing FDA approval of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.bridgetherapeutics.com
Disease Focus
STOCK CODENon Listed
Address
240 Summit Blvd., Suite 202, AL 35243
Birmingham
United States
Email
Contact Number
+1 877-223-6949

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/bridge-therapeutics-inc” connections=”true” suffix=””]